Bladder Cancer

At the 2021 Society of Urologic Oncology Annual Meeting, Alexander Kutikov, MD, FACS, gave a presentation on determining and helping improve the negative predictive value of cystoscopy in ruling out muscle invasive bladder cancer.

“I think discussing it and talking about the different techniques out there [is important],” says Svetlana Avulova, MD.

A study presented at the 2021 Society of Urologic Oncology Annual Meeting investigated adjuvant nivolumab in a population of patients with high risk of disease recurrence after radical surgery.

At the 2021 Society of Urologic Oncology Annual Meeting, a study was presented by Siv Venkat, MD, FRCSC, that evaluates the outcomes of the bladder-sparing method of segmental ureterectomy versus radical nephroureterectomy.

The antibody-drug conjugate was recommended for approval in the European Union based on findings from the phase 3 EV-301 trial.

"The problem is that we are not very good at predicting who is not harboring any cancer in their bladder,” says Alexander Kutikov, MD, FACS.

“The decrease of frequency in doing these procedures may not put improving the techniques of the procedure at the forefront of the surgeon's mind,” says Svetlana Avulova, MD.

"I'm hopeful and optimistic that over the next couple of years, we have some really reliable biomarkers to utilize in these patients who we know have frequent recurrences,"says Kristen Scarpato, MD, MPH.

Catch up on all the notable drug and device approvals in urology over the past year.

The FDA issued a complete response letter earlier this year regarding a biologics license application for the protein fusion drug in patients with BCG-unresponsive non–muscle invasive bladder cancer.

“I have no doubt that within 10 years…what we've been basing our treatment strategies and surveillance strategies of high-grade…papillary disease is still going to be there. But, in reality, we're really going to have a much better idea of individual risk stratification and characteristics of their tumors,” says Sam S. Chang, MD, MBA.

“We’re not doing enough lymph node dissections in upper tract disease,” says Siv Venkat, MD, FRCSC.

“The take-home message here is that adjuvant nivolumab improves disease-free survival in patients with muscle-invasive urothelial cancer at high risk for recurrence after surgery,” says Matthew D. Galsky, MD.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

“We are having a wealth of new medications that are helping our patients. Primarily with advanced disease, but…maybe there are going to be some applications to move that earlier and earlier in the in the disease process,” says Christopher B. Anderson, MD, MPH.

“There's unquestionably a real signal for…agents that are well tolerated that can be given for a long period of time,” says Sam S. Chang, MD, MBA.

“It is a promising drug in terms of the 3-month complete response rate,” says Chad Ritch, MD, MBA, FACS.

Multiple investigational agents have been developed and are being studied.

“We need better tests and better biomarkers to try to determine who still has residual cancer, even though they look like they don't,” says Christopher B. Anderson, MD, MPH.

“Fortunately, since things have…eased up with the pandemic, I would say probably in the last 6 months I've noticed that the BCG availability has improved,” says Chad R. Ritch, MD, MBA, FACS.

"There are going to be more trials open for those patients who may not have received BCG...I think that's essential, to realize that there are other treatments on the horizon for patients with non–muscle-invasive bladder cancer," says Sam S. Chang, MD.

"At the end of the day, the idea is that it shows you what your next steps are based on what the AUA and SUO guidelines are for non–muscle invasive bladder cancer," says Chad R. Ritch, MD, MBA, FACS.

All efficacy-evaluable patients reached a complete response with the combination regimen.

“I wouldn't be surprised if we have spotty distribution areas of concern for the next several years,” says Sam S. Chang MD, MBA, on the latest episode of the UT podcast Speaking of Urology.

"This study provides credible support for the expectation that post-RC HRQOL should recover and improve over the first 2 years after RC, and provides a benchmark for comparisons with future bladder preservation strategies," writes Badar M. Mian, MD.